JP6431528B2 - 癌治療のための薬物局所送達装置及び方法 - Google Patents
癌治療のための薬物局所送達装置及び方法 Download PDFInfo
- Publication number
- JP6431528B2 JP6431528B2 JP2016507662A JP2016507662A JP6431528B2 JP 6431528 B2 JP6431528 B2 JP 6431528B2 JP 2016507662 A JP2016507662 A JP 2016507662A JP 2016507662 A JP2016507662 A JP 2016507662A JP 6431528 B2 JP6431528 B2 JP 6431528B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- paclitaxel
- chemotherapeutic agent
- film
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 50
- 238000011282 treatment Methods 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 26
- 201000011510 cancer Diseases 0.000 title description 7
- 238000012377 drug delivery Methods 0.000 title description 6
- 239000003814 drug Substances 0.000 claims description 105
- 229940079593 drug Drugs 0.000 claims description 96
- 239000002246 antineoplastic agent Substances 0.000 claims description 54
- 229960001592 paclitaxel Drugs 0.000 claims description 51
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 50
- 229940127089 cytotoxic agent Drugs 0.000 claims description 49
- 229930012538 Paclitaxel Natural products 0.000 claims description 48
- 229920000642 polymer Polymers 0.000 claims description 31
- 229920006237 degradable polymer Polymers 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 230000015556 catabolic process Effects 0.000 claims description 20
- 238000006731 degradation reaction Methods 0.000 claims description 20
- 238000001727 in vivo Methods 0.000 claims description 18
- 210000000496 pancreas Anatomy 0.000 claims description 10
- 210000000232 gallbladder Anatomy 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 210000000813 small intestine Anatomy 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 210000003445 biliary tract Anatomy 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 238000013270 controlled release Methods 0.000 claims description 7
- 210000000013 bile duct Anatomy 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 210000000277 pancreatic duct Anatomy 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229910001260 Pt alloy Inorganic materials 0.000 claims description 2
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 2
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910010293 ceramic material Inorganic materials 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- 229910001256 stainless steel alloy Inorganic materials 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims 1
- 239000010410 layer Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000002642 intravenous therapy Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012667 polymer degradation Methods 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 206010056375 Bile duct obstruction Diseases 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000000893 fibroproliferative effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000009812 gallbladder lymphoma Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002897 polymer film coating Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/041—Bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0021—Angular shapes square
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Description
本出願は、参照により本明細書に組み込まれる、2013年4月10日出願の、米国仮特許出願第61/810,543号の優先権を主張するものである。
本開示は、概して薬物送達装置及び方法の分野におけるものであり、より具体的には、例えば膵臓、胆道系、胆嚢、肝臓、小腸、または結腸の腫瘍の治療における、必要とされる組織部位への局所的な薬物の制御放出を提供する埋め込み型装置及び方法に関する。
Claims (28)
- 組織部位に配置され、治療上有効な量の化学療法薬を放出することによって、治療を必要とする患者の前記組織部位に前記化学療法薬を局所投与することによる、膵臓、胆道系、胆嚢、肝臓、小腸、または結腸の腫瘍の前記治療に使用するためのパクリタキセルを含む前記化学療法薬を含む薬品であって、
前記薬品が、乳酸−グリコール酸共重合体を含む分解性ポリマー及び前記化学療法薬の混合物を含むフィルムを備え、
前記フィルムが、約2μm〜約1000μmの厚さを有し、
前記フィルムからの前記治療上有効な量の前記化学療法薬の前記放出が、前記組織部位における前記ポリマーのインビボ分解によって制御され、
前記治療上有効な量の前記化学療法薬の前記放出が、前記薬品を前記組織部位へ配置した後の約1日〜約14日の遅延期間に続いて起こる、
前記薬品。 - 前記組織部位が膵胆組織部位を含む、請求項1に記載の前記薬品。
- 前記組織部位が腹腔内組織部位を含む、請求項1または2に記載の前記薬品。
- 前記遅延期間後の、前記治療上有効な量の前記化学療法薬の前記放出が、少なくとも3日間にわたって実質的に直線的な初期放出速度を有する、請求項1〜3いずれか1項に記載の前記薬品。
- 前記遅延期間が2〜4日間である、請求項1〜3いずれか1項に記載の前記薬品。
- 前記遅延期間中に治療有効量未満の量の前記化学療法薬が放出される、請求項1〜3いずれか1項に記載の前記薬品。
- 前記分解性ポリマーの前記インビボ分解が、加水分解性の分解である、請求項1〜6のいずれか1項に記載の前記薬品。
- 放出される前記パクリタキセルの前記治療上有効な量が、少なくとも約1mg/日である、請求項1〜7のいずれか1項に記載の前記薬品。
- 放出される前記パクリタキセルの前記治療上有効な量が、5mg/日〜125mg/日の平均量にある、請求項8に記載の前記薬品。
- 前記治療上有効な量のパクリタキセルが、約10日〜約90日の治療期間にわたって放出される、請求項8または9に記載の前記薬品。
- 前記フィルムが、約5μm〜約500μmの厚さを有する、請求項1〜10のいずれか1項に記載の前記薬品。
- 前記混合物が、約1重量%〜約10重量%のパクリタキセルを含む、請求項1〜11のいずれか1項に記載の前記薬品。
- 前記薬品が、前記フィルムが接着する生体適合性基層をさらに備える、請求項1〜12のいずれか1項に記載の前記薬品。
- 前記基層がステントを備え、前記薬品が前記患者の胆管または膵管に配置される、請求項13に記載の前記薬品。
- 前記基層が、可撓性パッチ、硬性パッチ、またはメッシュを備え、前記薬品が前記腫瘍上に直接配置される、請求項13に記載の前記薬品。
- 前記分解性ポリマーが、配置後約1日〜約12ヶ月の期間内で分解するように構成される、請求項1〜15のいずれか1項に記載の前記薬品。
- 膵臓、胆道系、胆嚢、肝臓、小腸、または結腸の腫瘍の治療のための薬物溶出装置であって、
約2μm〜約1000μmの厚さを有し、かつ分解性ポリマー及び化学療法薬の混合物を含むフィルムと、該フィルムが接着した、パッチまたはメッシュを含む可撓性生体適合性基層を備え、
前記装置が、患者の組織部位における前記腫瘍上に直接配置するように構成され、前記フィルムが、前記腫瘍を治療するために、前記組織部位における前記ポリマーのインビボ分解によって前記組織部位への治療上有効な量の前記化学療法薬の制御放出を提供するように構成される、
前記治療上有効な量の前記化学療法薬の前記放出が、前記装置を前記組織部位へ配置した後の約1日〜約14日の遅延期間に続いて起こる、
前記薬物溶出装置。 - 前記遅延期間後の、前記治療上有効な量の前記化学療法薬の前記放出が、少なくとも3日間にわたって実質的に直線的な初期放出速度を有する、請求項17に記載の前記装置。
- 前記分解性ポリマーが加水分解性の分解性ポリマーである、請求項17または18のいずれか1項に記載の前記装置。
- 前記分解性ポリマーが乳酸−グリコール酸共重合体を含む、請求項17〜19のいずれか1項に記載の前記装置。
- 前記化学療法薬が、パクリタキセル、ゲムシタビン、nab−パクリタキセル、5−フルオロウラシル、オキサリプラチン、イリノテカン、及びそれらの組み合わせからなる群から選択される、請求項17〜20のいずれか1項に記載の前記装置。
- 前記化学療法薬がパクリタキセルであり、前記治療上有効な量が、少なくとも約1mg/日の前記パクリタキセルである、請求項17〜21のいずれか1項に記載の前記装置。
- 前記治療上有効な量のパクリタキセルが、約10日〜約90日の治療期間にわたって放出される、請求項22に記載の前記装置。
- 前記治療上有効な量が、5mg/日〜125mg/日の平均量の前記パクリタキセルを含む、請求項22に記載の前記装置。
- 前記フィルムが、約5μm〜約500μmの厚さを有する、請求項17〜24のいずれか1項に記載の前記装置。
- 前記混合物が、約1重量%〜約10重量%のパクリタキセルまたは他の化学療法薬を含む、請求項17に記載の前記装置。
- 前記基層が、金属、ポリマー、またはセラミック材料を含む、請求項17〜26のいずれか1項に記載の前記装置。
- 前記基層が、ステンレス鋼合金、コバルトクロム合金、ニチノール、白金合金、チタン合金、シリコーン、延伸ポリテトラフルオロエチレン(ePTFE)、またはポリエチレンを含む、請求項17〜26のいずれか1項に記載の前記装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361810543P | 2013-04-10 | 2013-04-10 | |
US61/810,543 | 2013-04-10 | ||
PCT/US2014/033671 WO2014169137A1 (en) | 2013-04-10 | 2014-04-10 | Local drug delivery devices and methods for treating cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018207608A Division JP2019034962A (ja) | 2013-04-10 | 2018-11-02 | 癌治療のための薬物局所送達装置及び方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016516780A JP2016516780A (ja) | 2016-06-09 |
JP2016516780A5 JP2016516780A5 (ja) | 2017-06-08 |
JP6431528B2 true JP6431528B2 (ja) | 2018-11-28 |
Family
ID=50841949
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016507662A Active JP6431528B2 (ja) | 2013-04-10 | 2014-04-10 | 癌治療のための薬物局所送達装置及び方法 |
JP2018207608A Pending JP2019034962A (ja) | 2013-04-10 | 2018-11-02 | 癌治療のための薬物局所送達装置及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018207608A Pending JP2019034962A (ja) | 2013-04-10 | 2018-11-02 | 癌治療のための薬物局所送達装置及び方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US9301926B2 (ja) |
EP (1) | EP2983730B1 (ja) |
JP (2) | JP6431528B2 (ja) |
CA (1) | CA2944480C (ja) |
ES (1) | ES2762555T3 (ja) |
WO (1) | WO2014169137A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2890386A2 (en) | 2012-08-31 | 2015-07-08 | TARIS Biomedical LLC | Drug delivery systems and methods for treatment of prostate |
AU2015280204B2 (en) | 2014-06-23 | 2018-10-18 | Xlink Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
EP3302431B1 (en) | 2015-06-04 | 2020-11-11 | Crititech, Inc. | Taxane particles and their use |
DK3303339T3 (da) | 2015-07-07 | 2021-04-12 | H Lundbeck As | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme |
CN109475492B (zh) | 2016-04-04 | 2022-04-29 | 克里蒂泰克公司 | 实体肿瘤治疗方法 |
AU2017292650A1 (en) | 2016-07-06 | 2018-12-13 | H. Lundbeck A/S | PDE9 inhibitors for treatment of peripheral diseases |
CA3063418A1 (en) * | 2017-05-17 | 2018-11-22 | Massachusetts Institute Of Technology | Self-actuating articles |
WO2018218104A1 (en) | 2017-05-26 | 2018-11-29 | Imara, Inc. | Methods of making and using pde9 inhibitors |
JP2020523285A (ja) | 2017-06-09 | 2020-08-06 | クリチテック,インコーポレイテッド | 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療 |
SG11201909837YA (en) | 2017-06-14 | 2019-11-28 | Crititech Inc | Methods for treating lung disorders |
CA3071014A1 (en) | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | Methods of treating tumor metastasis |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
JP7105505B2 (ja) * | 2017-11-30 | 2022-07-25 | ディー. ドスタ、アナトリ | 生体組織への局所曝露方法、組織置換アプリケーターおよび多孔質ポリテトラフルオロエチレンの使用 |
SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク. | 6−[(3S,4S)−4−メチル−l−(ピリミジン−2−イルメチル)ピロリジン−3−イル]−3−テトラヒドロピラン−4−イル−7H−イミダゾ[l,5−A]ピラジン−8−オンの一水和物および結晶形態 |
US20230149299A1 (en) * | 2021-11-17 | 2023-05-18 | PanTher Therapeutics, Inc. | Implantable and biodegradable drug delivery devices and methods of use thereof |
US20240024644A1 (en) * | 2022-07-22 | 2024-01-25 | PanTher Therapeutics, Inc. | Tissue penetrating and biodegradable drug delivery devices and methods of use thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US20050271701A1 (en) | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9216239B2 (en) | 2001-06-08 | 2015-12-22 | Leo Rubin | Medical device for intra-lumenal delivery of pharmaceutical agents |
JP2005160600A (ja) * | 2003-12-01 | 2005-06-23 | Ir:Kk | 液含浸性ステント及び薬液含浸ステント |
JP5028605B2 (ja) | 2004-11-22 | 2012-09-19 | 国立大学法人九州大学 | バイオフィルム形成阻害剤及び治療用器具 |
US20110118827A1 (en) | 2005-06-06 | 2011-05-19 | Dr. Tim Wu | Biodegradable stent formed with polymer-bioceramic nanoparticle composite and method of making the same |
US20070178138A1 (en) | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
WO2007127488A1 (en) | 2006-04-27 | 2007-11-08 | Shenoy Narmada R | Compositions and methods for treating or preventing diseases of body passageways |
JP2007313009A (ja) * | 2006-05-25 | 2007-12-06 | Terumo Corp | ステント |
US9474833B2 (en) * | 2006-12-18 | 2016-10-25 | Cook Medical Technologies Llc | Stent graft with releasable therapeutic agent and soluble coating |
KR100904207B1 (ko) | 2007-06-01 | 2009-06-25 | (주) 태웅메디칼 | 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트 |
AU2008202283B2 (en) | 2007-06-01 | 2011-01-20 | Kyong-Min Shin | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith |
KR100988816B1 (ko) | 2008-01-29 | 2010-10-20 | 신경민 | 담즙관용 이중 피막형 스텐트 |
MX2011006167A (es) * | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
WO2011022623A2 (en) * | 2009-08-21 | 2011-02-24 | Boston Scientific Scimed, Inc. | Medical devices containing therapeutic agents |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US20120150282A1 (en) | 2010-12-10 | 2012-06-14 | Biotronik Ag | Implant having a paclitaxel-releasing coating |
US20120323311A1 (en) | 2011-04-13 | 2012-12-20 | Micell Technologies, Inc. | Stents having controlled elution |
CN102727944A (zh) * | 2011-11-14 | 2012-10-17 | 上海市第一人民医院 | 抗胆管良、恶性狭窄的药物涂层支架及制备方法 |
EP2725103A3 (en) | 2011-11-14 | 2016-01-06 | Silenseed Ltd | Methods and compositions for treating prostate cancer |
US8834902B2 (en) * | 2012-03-09 | 2014-09-16 | Q3 Medical Devices Limited | Biodegradable supporting device |
-
2014
- 2014-04-10 US US14/250,025 patent/US9301926B2/en active Active
- 2014-04-10 JP JP2016507662A patent/JP6431528B2/ja active Active
- 2014-04-10 ES ES14727109T patent/ES2762555T3/es active Active
- 2014-04-10 CA CA2944480A patent/CA2944480C/en active Active
- 2014-04-10 EP EP14727109.2A patent/EP2983730B1/en active Active
- 2014-04-10 WO PCT/US2014/033671 patent/WO2014169137A1/en active Application Filing
-
2016
- 2016-02-26 US US15/055,012 patent/US11167066B2/en active Active
-
2018
- 2018-11-02 JP JP2018207608A patent/JP2019034962A/ja active Pending
-
2021
- 2021-11-08 US US17/520,891 patent/US20220054719A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220054719A1 (en) | 2022-02-24 |
CA2944480C (en) | 2021-05-18 |
WO2014169137A1 (en) | 2014-10-16 |
US9301926B2 (en) | 2016-04-05 |
JP2019034962A (ja) | 2019-03-07 |
CA2944480A1 (en) | 2014-10-16 |
US11167066B2 (en) | 2021-11-09 |
ES2762555T3 (es) | 2020-05-25 |
JP2016516780A (ja) | 2016-06-09 |
US20140308336A1 (en) | 2014-10-16 |
US20160175491A1 (en) | 2016-06-23 |
EP2983730B1 (en) | 2019-10-16 |
EP2983730A1 (en) | 2016-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6431528B2 (ja) | 癌治療のための薬物局所送達装置及び方法 | |
Yi et al. | A 3D-printed local drug delivery patch for pancreatic cancer growth suppression | |
RU2242974C2 (ru) | Композиции и способы лечения или предупреждения воспалительных заболеваний | |
ES2445097T3 (es) | Dispositivos médicos implantables y revestimientos para los mismos comprendiendo copolímeros bloque y copolímeros de polietilenglicol y un poli(láctido-glicoido) | |
Moon et al. | An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis | |
JP5153340B2 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
Poláková et al. | Electrospun nanofibers for local anticancer therapy: Review of in vivo activity | |
JP2021107420A (ja) | 埋込み型薬物送達組成物およびその使用法 | |
JP2013212418A (ja) | 一時的補剛メッシュ補綴具 | |
TW200800196A (en) | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices | |
JP2016516780A5 (ja) | ||
US20060193893A1 (en) | Medical devices | |
KR20200032159A (ko) | 종양 전이를 치료하는 방법 | |
US8017143B2 (en) | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith | |
Li et al. | Silk-coated dexamethasone non-spherical microcrystals for local drug delivery to inner ear | |
CN101959542B (zh) | 药物传递系统 | |
KR101324772B1 (ko) | 약물의 제어 전달이 가능한 식도 스텐트 및 이의 제조방법 | |
KR100916750B1 (ko) | 약물 방출 스텐트용 코팅제와 약물 방출 스텐트용 코팅제의제조방법 | |
Park et al. | In vitro/in vivo evaluation of NCDS-micro-fabricated biodegradable implant | |
ES2948916T3 (es) | Nanopartículas de óxido nítrico sintasa para el tratamiento de la enfermedad vascular | |
CN102363052A (zh) | 携带短链神经酰胺的药物支架 | |
EP4056207A1 (en) | Drug-loaded implanted medical device and preparation method therefor | |
US20210161807A1 (en) | Implantable device for localized drug delivery, uses and manufacturing method thereof | |
Rodríguez-Martínez et al. | Preclinical safety study of a gemcitabine-controlled release polymer for locoregional administration in pancreatic cancer | |
WO2023133558A2 (en) | Localized drug delivery to prevent vascular restenosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170410 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180126 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6431528 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |